US OptionsDetailed Quotes
VRTX250509C480000
- 26.10
- 0.000.00%
15min DelayTrading May 2 10:33 ET
0.00High0.00Low
0.00Open26.10Pre Close0 Volume60 Open Interest480.00Strike Price0.00Turnover54.21%IV0.27%PremiumMay 9, 2025Expiry Date24.74Intrinsic Value100Multiplier4DDays to Expiry1.36Extrinsic Value100Contract SizeAmericanOptions Type0.8155Delta0.0091Gamma18.16Leverage Ratio-0.9906Theta0.0438Rho14.81Eff Leverage0.1436Vega
Vertex Pharmaceuticals Stock Discussion
Revolutionary CF Treatment Pioneer at Vertex Receives Top Medical Honor: How It Transforms Patient Care
Major EU Victory: KAFTRIO Now Approved for 4,000 More CF Patients, Including Children
Revolutionary Gene Therapy CASGEVY Now Available Through NHS England: Major Win for Sickle Cell Patients
FDA Approves First Non-Opioid Pain Drug in 20 Years: Vertex's Game-Changing Alternative to Opioids
has options
“Suzetrigine: The FDA has assigned a PDUFA target action date of January 30, 2025, for suzetrigine for the treatment of moderate-to-severe acute pain. Suzetrigine was granted Priority Review by the FDA.
The Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act became effective on January 1st, 2025. The NOPAIN Act mandates that Medicare provide a separate add-on payment in the hospital outp...
nfa
SiteOne’s efforts in non-opioid pain management put it in a unique position relative to Vertex Pharmaceuticals, a major player in the field known for its successful development of cystic fibrosis treatments. Vertex has also been working on non-opioid pain drugs, specifically targeting the NaV1.8 sodium channel, a focal point shared by SiteOne’s lead pro...
At 4:02 p.m. ET, the three indices closed lower. The $Dow Jones Industrial Average (.DJI.US)$ was off 0.70%, losing 300 points. The $S&P 500 Index (.SPX.US)$ was down 1.32% and the $Nasdaq Composite Index (.IXIC.US)$ was off 2.24%.
MACRO
In macro, core retail sales grew by 0.1% month over month, lower than estimated. ...
No comment yet